Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Equity (2016 - 2025)

Historic Return on Equity for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 0.7%.

  • Northwest Biotherapeutics' Return on Equity fell 1900.0% to 0.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.7%, marking a year-over-year decrease of 1900.0%. This contributed to the annual value of 0.93% for FY2024, which is 3000.0% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Return on Equity stood at 0.7% for Q3 2025, which was down 1900.0% from 0.73% recorded in Q2 2025.
  • Northwest Biotherapeutics' Return on Equity's 5-year high stood at 1.12% during Q2 2023, with a 5-year trough of 0.09% in Q4 2023.
  • In the last 5 years, Northwest Biotherapeutics' Return on Equity had a median value of 0.66% in 2022 and averaged 0.59%.
  • In the last 5 years, Northwest Biotherapeutics' Return on Equity plummeted by -5600bps in 2023 and then soared by 8000bps in 2024.
  • Northwest Biotherapeutics' Return on Equity (Quarter) stood at 0.27% in 2021, then soared by 128bps to 0.62% in 2022, then plummeted by -86bps to 0.09% in 2023, then skyrocketed by 888bps to 0.85% in 2024, then decreased by -17bps to 0.7% in 2025.
  • Its last three reported values are 0.7% in Q3 2025, 0.73% for Q2 2025, and 0.78% during Q1 2025.